September 20, 2018 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

Early Access to IsoPlexis’ Single Cell Analytics Platform Enhances Cell Therapy Program at World-renowned Research and Treatment Center

IsoPlexis’ groundbreaking platform has been shown in key studies to predict patient response to cell therapy The IsoLight® platform: • profiles responses at the single cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex patient response to cancer immunotherapies • advances high-need areas of cell therapy research,... Read more

August 20, 2018 Cell Analysis Tools M&A, Partnerships

IsoPlexis Announces Expansion into Asia Pacific

IsoPlexis expands sales of its single-cell proteomic analysis platform, IsoLight and IsoCode Chip, to the pharmaceutical and life sciences markets in China BRANFORD, Conn., Aug. 20, 2018 /PRNewswire/ — IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology, announced today an exclusive agreement with Tekon Biotech, a leading instrumentation distributor, to... Read more

July 24, 2018 Cell Analysis Tools Clinical Research/Diagn.

IsoPlexis Places IsoLight Single-Cell Proteomic Detection Instrument at Fred Hutchinson Cancer Research Center

The IsoLight is a first-of-its-kind system for high-throughput, single-cell functional proteomic detection BRANFORD, Conn., July 24, 2018 /PRNewswire/ — IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology, has installed its ground-breaking IsoLight benchtop system at Fred Hutchinson Cancer Research Center, as part of the company’s Early Adopter Program. The sample-to-answer... Read more